Hereditary Angioedema due to C1 Inhibitor Deficiency: C1-INH Replacement Therapy
DOI:
https://doi.org/10.7175/rhc.v5i2.913Keywords:
Hereditary angioedema, C1 inhibitor deficiency, Replacement therapyAbstract
Hereditary angioedema (HAE) is a rare condition affecting about 1 in 50.000 individuals and caused by a mutation in the gene encoding the C1-esterase inhibitor (C1-INH), which is involved in the control of complement, clotting, fibrinolytic and kinin pathways. HAE is characterized by plasma outflow from blood vessels, leading to fluid collecting (edema) in the deep tissue layers of the face, larynx, abdomen, and extremities. Three different types of HAE have been identified: in type I the mutation leads to the lack of production of C1-INH, in type II the mutation leads to the production of dysfunctional C1-INH, while type III is extremely rare and still not fully understood. Therapeutic approaches for HAE include on-demand treatments to stop angioedema attacks and prophylactic treatment to prevent attacks both by pre-procedural (short-term) and routine (long-term) prophylaxis. Aim of the present review is to present an overview of C1-INH replacement therapy with the plasma-derived concentrate of C1-INH Berinert® (CSL Behring GmbH) in the treatment of type I and II HAE.
References
Carr TF, Saltoun CA. Urticaria and Angioedema. Allergy asthma Proc 2012; 33(S1): S70-2; http://dx.doi.org/10.2500/aap.2012.33.3554
Cicardi M, Bellis P, Bertazzoni G, et al. Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts. Intern Emerg Med 2014; 9: 85-92; http://dx.doi.org/10.1007/s11739-013-0993-z
Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-7; http://dx.doi.org/10.1016/S0140-6736(97)09137-X
Davis AE 3rd. Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 2008; 100: 7-12; http://dx.doi.org/10.1016/S1081-1206(10)60580-7
Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15: 69-78; http://dx.doi.org/10.1016/j.molmed.2008.12.001
Kaplan AP, Joseph K. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway. Adv Immunol 2014; 121: 41-89; http://dx.doi.org/10.1016/B978-0-12-800100-4.00002-7
Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 8(S3): S51–S131; http://dx.doi.org/10.1016/j.jaci.2004.06.047
Zuraw BL. Hereditary angioedema. N Engl J Med 2008; 359: 1027-36; http://dx.doi.org/10.1056/NEJMcp0803977
Vasekar M, Craig TJ. ACE inhibitor-induced angioedema. Curr Allergy Asthma Rep 2012; 12: 72-8; http://dx.doi.org/10.1007/s11882-011-0238-z
Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29: 2273-7; http://dx.doi.org/10.1097/HJH.0b013e32834b4b9b
Cicardi M, Zanichelli A. The acquired deficiency of C1-inhibitor: lymphoproliferation and angioedema. Curr Mol Med 2010; 10: 354-60; http://dx.doi.org/10.2174/156652410791317066
Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 2006; 26: 709-24; http://dx.doi.org/10.1016/j.iac.2006.09.003
Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012; 33(S1): S145-56; http://dx.doi.org/10.2500/aap.2012.33.3627
Nzeako UC, Longhurst HJ. Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Eur J Gastroenterol Hepatol 2012; 24: 353-61
Cancian M, Vettore G, Realdi G. An uncommon case of acute pancreatitis. Gastroenterology 2011; 140: 33, 370
Arcoleo F, Bova M, Cancian M, et al. Angioedema ereditario da carenza di C1 inibitore. Consensus Document italiano per la diagnosi e la terapia. Giorn It Allergol Immunol Clin 2008: 18: 114-22
Bowen T, Cicardi M, Farkas H, et al 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6: 24; http://dx.doi.org/10.1186/1710-1492-6-24
Tarzi MD, Hickey A, Forster T, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angioedema: assay evaluation and reccomandations. Clin Exp Immunol 2007; 149: 513-6; http://dx.doi.org/10.1111/j.1365-2249.2007.03438.x
Ebo DG, Kathleen J, De Knop KJ, et al. Hereditary Angioedema in Childhood. An Approach to Management. Pediatr Drugs 2010; 12: 257-68; http://dx.doi.org/10.2165/11532590-000000000-00000
Craig T, Pursun EA, Bork K, et al. WAO guidelines for the management of Hereditary angioedema. WAO Journal 2012; 5: 182-99
Cicardi M, Bork K, Caballero T, et al. Evidence-based reccomandations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67: 147-57; http://dx.doi.org/10.1111/j.1398-9995.2011.02751.x
Wahn V, Aberer W, Ebert W, et al. Hereditary angioedema (HAE) in children and adolescents – a consensus on therapeutic strategies. Eur J Pediatr 2012; 171: 1339-48; http://dx.doi.org/10.1007/s00431-012-1726-4
Cicardi M, Craig TJ, Martinez-Saguer I, et al. Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 2013; 161: S3-9; http://dx.doi.org/10.1159/000351232
Pickering RJ, Good RA, Kelly JR, et al. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet 1969; 1: 326-30; http://dx.doi.org/10.1016/S0140-6736(69)91295-1
Keating GM. Human C1-Esterase Inhibitor Concentrate (Berinert). Biodrugs 2009; 23: 399-406; http://dx.doi.org/10.2165/11201100-000000000-00000
De Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci 2003; 29: 247-54; http://dx.doi.org/10.1016/j.transci.2003.08.006
Groner A, Nowak T, Schafer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 2012; 52: 2104-12; http://dx.doi.org/10.1111/j.1537-2995.2012.03590.x
Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared to placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124: 801-8; http://dx.doi.org/10.1016/j.jaci.2009.07.017
Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks - final results of the I.M.P.A.C.T.2 study. Allergy 2011; 66: 1604-11; http://dx.doi.org/10.1111/j.1398-9995.2011.02702.x
Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001; 161: 714-8; http://dx.doi.org/10.1001/archinte.161.5.714
Schneider L, Hurewitz D, Wasserman R, et al. C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. Studies. Pediatr Allergy Immunol 2013: 24: 54-60; http://dx.doi.org/10.1111/pai.12024
Hack CE, Relan A, van Amersfoort ES, et al. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy 2012; 67: 123-30; http://dx.doi.org/10.1111/j.1398-9995.2011.02716.x
Bork K, Steffensen I, Machnig T. Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review. Allergy Asthma Proc 2013; 34: 312-27; http://dx.doi.org/10.2500/aap.2013.34.3677
Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129: 308-20; http://dx.doi.org/10.1016/j.jaci.2011.11.025
Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema:
a viable, effective treatment option. Clin Exp Immunol 2006; 147: 11-7
Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009; 19: 147-51
Kreuz W, Rusicke E, Martinez-Saguer I, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012; 52: 100-7; http://dx.doi.org/10.1111/j.1537-2995.2011.03240.x
Zuraw BL, Busse PJ, Jacobs J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363: 513-22; http://dx.doi.org/10.1056/NEJMoa0805538
Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126: 821-7; http://dx.doi.org/10.1016/j.jaci.2010.07.021
Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-41; http://dx.doi.org/10.1056/NEJMoa0906393
Bork K, Hardt J, Staubach-Renz P, et al. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 112: 58-64; http://dx.doi.org/10.1016/j.tripleo.2011.02.034
Farkas H, Zotter Z, Csuka D, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor - a long-term survey. Allergy 2012; 67: 1586-93
Farkas H, Varga L, Szeplaki G, et al. Management of hereditary angioedema in pediatric patients. Pediatrics 2007; 120: 713-22; http://dx.doi.org/10.1542/peds.2006-3303
Frank MM, Sergent JS, Kane MA, et al. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976; 295: 1444-8; http://dx.doi.org/10.1056/NEJM197612232952602
Bork K, Bygum A, Hardt J. Benefits and risk of danazol in hereditary angioedema: a long term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100: 153-61; http://dx.doi.org/10.1016/S1081-1206(10)60424-3
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
